Table I.
Characteristics of patients and disease status.
| Parameter | Patients, n (%) |
|---|---|
| Total patients | 63 (100) |
| Age, years | |
| ≥60 | 35 (56) |
| <60 | 28 (44) |
| Gender | |
| Male | 25 (40) |
| Female | 38 (60) |
| Localization of tumor | |
| Cardia | 21 (33) |
| Antrum | 27 (43) |
| Undetermined | 15 (24) |
| Histology | |
| Adenocarcinoma | 42 (67) |
| Signet-ring cell | 21 (33) |
| Grade | |
| I–II | 10 (16) |
| III | 44 (70) |
| Undetermined | 9 (14) |
| Tumor (T) stage | |
| 1–3 | 14 (22) |
| 4 | 22 (35) |
| Unknown | 27 (43) |
| No. of involved lymph node | |
| 0–2 | 12 (19) |
| ≥3 | 13 (21) |
| Unknown | 38 (60) |
| Disease stage | |
| Non-metastatic | 32 (51) |
| Metastatic | 31 (49) |
| Liver metastasisa | |
| Yes | 14 (45) |
| No | 17 (55) |
| Curative surgeryb | |
| Yes | 17 (53) |
| No | 9 (28) |
| Unknown | 6 (19) |
| Hemoglobin level, g/dl | |
| Low, <12 | 35 (56) |
| Normal, ≥12 | 28 (44) |
| WBC count | |
| Normal, <10,000 | 52 (83) |
| High, ≥10,000 | 11 (17) |
| Platelet count | |
| Normal, <350,000 | 54 (86) |
| High, >350,000 | 9 (14) |
| LDH level, U/l | |
| Normal, <450 | 43 (68) |
| High, ≥450 | 10 (16) |
| Unknown | 10 (16) |
| ESR, /h | |
| High, ≥50 | 16 (25) |
| Normal, <50 | 10 (16) |
| Unknown | 37 (59) |
| CEA level, ng/ml | |
| Normal, <10 | 44 (70) |
| High, ≥10 | 13 (21) |
| Unknown | 6 (9) |
| CA 19–9 level, IU/ml | |
| Normal, <40 | 32 (51) |
| High, ≥40 | 25 (40) |
| Unknown | 6 (9) |
| Chemotherapy responsiveness | |
| Responsive | 13 (43) |
| Non-responsive | 17 (57) |
| Last status | |
| Alive | 28 (44) |
| Succumbed | 35 (56) |
a
In metastatic patients
b
in nonmetastatic patients. WBC, white blood cell; LDH, lactate dehydrogenase; ESR, erythrocyte sedimentation rate; CEA, carcinoembryonic antigen; CA 19–9, carbohydrate antigen 19–9.